Patients living with HIV who were frail or prefrail had significantly poorer oral health-related quality of life compared with patients with HIV who were robust.
Avtozma, the third biosimilar to Actemra, has received FDA approval for multiple inflammatory diseases and COVID-19, potentially expanding treatment access for patients.